GlaxoSmithKline (GSK) Reports Q2 EPS of GBP0.27
Get Alerts GSK Hot Sheet
Join SI Premium – FREE
GlaxoSmithKline (NYSE: GSK) reported Q2 EPS of GBP0.27, GBP0.01 better than the analyst estimate of GBP0.26. Revenue for the quarter came in at GBP7.32 million versus the consensus estimate of GBP7.28 million.
Financial highlights | ||
| ||
| · | Pharmaceutical sales, £4.4 billion, +12% AER, +3% CER, Vaccines sales, £1.1 billion, +16% AER, +5% CER, Consumer Healthcare sales, £1.9 billion,+10% AER, flat at CER |
| · | Group operating margin 28.5%; Pharmaceuticals 33.6%; Vaccines 33.7%; Consumer 17.7% |
| · | Total Q2 loss per share of 3.7p reflecting charges resulting from increases in the valuation of Consumer and HIV businesses and new portfolio choices |
| · | Updated 2017 guidance: Adjusted EPS growth now expected to be 3% to 5% CER reflecting impact of Priority Review Voucher |
| · | H1 Free Cash Flow £0.4 billion (H1 2016: £0.1 billion) |
| · | 19p dividend declared for Q2; continue to expect 80p for FY 2017 |
| ||
Product and pipeline highlights | ||
|
|
|
| · | New product sales of £1.7 billion, +62% AER, +47% CER |
| · | HIV two drug regimen (dolutegravir and rilpivirine) filed for approval in US and EU |
| · | Shingrix filed for approval in Japan |
| · | FDA approval received for subcutaneous Benlysta for treatment of SLE |
|
|
|
New business priorities to 2020 | ||
|
|
|
| · | New priorities to strengthen innovation, improve performance and build trust |
| · | Pharmaceutical R&D pipeline reviewed with target over time to allocate 80% of capital to priority assets in two current (Respiratory and HIV/infectious diseases) and two potential (Oncology and Immuno-inflammation) therapy areas; more than 30 pre-clinical and clinical programmes to be stopped |
| · | Extended cost reduction programme expected to deliver additional £1 billion annual cost savings by 2020 driven by new business priorities, improved supply chain efficiency and reduced administrative costs |
| · | Enhanced focus on improved cash generation and strengthening credit profile |
| · | Dividend of 80p expected for 2018 in conjunction with new dividend policy |
| · | Group outlook for 2020: Expected 5 year percentage CAGR to 2020 on a CER basis for sales of low-to-mid-single digits and Adjusted EPS of mid-to-high single digits |
| Q2 2017 |
| Growth |
| H1 2017 |
| Growth | ||||
| £m |
| £% |
| CER% |
| £m |
| £% |
| CER% |
|
|
|
|
|
|
|
|
|
|
|
|
Turnover | 7,320 |
| 12 |
| 3 |
| 14,704 |
| 15 |
| 4 |
|
|
|
|
|
|
|
|
|
|
|
|
Total operating (loss)/profit | (20) |
| 87 |
| (45) |
| 1,698 |
| >100 |
| >100 |
Adjusted operating profit | 2,083 |
| 14 |
| - |
| 4,062 |
| 21 |
| 4 |
|
|
|
|
|
|
|
|
|
|
|
|
Total (loss)/earnings per share | (3.7)p |
| 59 |
| 29 |
| 17.7p |
| >100 |
| >100 |
Adjusted earnings per share | 27.2p |
| 12 |
| (2) |
| 52.1p |
| 20 |
| 3 |
|
|
|
|
|
|
|
|
|
|
|
|
Net cash from operations | 1,008 |
| (18) |
|
|
| 2,152 |
| 24 |
|
|
Free cash flow | (282) |
| >(100) |
|
|
| 368 |
| >100 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For earnings history and earnings-related data on GlaxoSmithKline (GSK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
- Snap shares surge 26% on earnings beat, optimistic outlook
- Byline Bancorp (BY) Tops Q1 EPS by 6c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Dividend, Earnings, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!